RxDoctor Payments Data

Angela Huizenga, OD

Optometrist · Grand Rapids, MINPI 1275861031

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 79 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$361
  • Biotissue Holdings Inc.$260
  • Sun Pharmaceutical Industries Inc.$248
  • Bausch & Lomb Americas Inc.$129
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$123
  • Alcon$110
  • plus $562 from 10 others

What the payments were for

  • Food & beverage$1,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,793 in reported general payments places this provider in the 80th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan

Medicare billing

Part B allowed, 2024
$21,686
Medicare patients
145
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine148$108,489
XiidraLifitegrast35$36,285
CequaCyclosporine36$23,817
LumiganBimatoprost50$17,889
Bimatoprost50$6,664
VyzultaLatanoprostene Bunod20$6,291
Cyclosporine16$3,876
Latanoprost111$1,662
Timolol Maleate55$902
Prednisolone Acetate18$619
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$351
Doxycycline Monohydrate16$349
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$361$126,379198 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$129$42,57655 claims
Sun Pharmaceutical Industries Inc.Cequa$248$23,81736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →